内皮機能障害の治療のための超音波で誘発される天然の酸化窒素ブースター
Yuqiong Wang1, Dong Meng2, Yu Dong1
1College of Chemistry, Chemical Engineering and Materials Science, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Collaborative Innovation Center of Functionalized Probes for Chemical Imaging in Universities of Shandong, Institutes of Biomedical Sciences, Shandong Normal University Jinan 250014 Shandong China gaowen@sdnu.edu.cn lipingwang@sdnu.edu.cn.
Chemical science
|August 29, 2025
まとめ
超音波で誘発される新しい酸化窒素 (NO) ブースター,FPGは,動脈硬化症における内皮機能障害と闘います. この治療法では プラークの蓄積を減らし 血管の整合性を保ち 心血管疾患の治療に 有望な戦略を提示します
科学分野:
- バイオメディカルエンジニアリング
- 心血管研究
- ナノ医療
背景:
- 血管内皮機能不全は,炎症,酸化ストレス,窒素酸化物 (NO) 枯渇によって特徴づけられる動脈硬化症 (AS) の鍵です.
- 外因的なNO投与は血管の恒常性を維持する戦略ですが,安全で効果的な方法が必要です.
研究 の 目的:
- 内皮機能障害の治療のために,自然で超音波 (US) 誘発された,オンデマンドのNOブースター (FPG) を開発する.
- 分子経路と動脈硬化マウスモデルにおけるFPGの治療効果を調査する.
主な方法:
- FPGはS-ニトロスグルタチオン (GSNO) とフコイドンを使用して合成されています.
- オックス-LDL刺激のHUVECにおけるRNA配列とウェスタンブロット分析.
- 高脂肪食のマウスを用いた体内試験で,USとヒト病理学的イメージングを用いた.
主要な成果:
- HUVECにおけるUS活性化FPG調節されたNrf2,NF-κBおよびVEGF/eNOS経路.
- FPG治療は酸化ストレスや炎症を軽減し,血管新生を強めた.
- FPGとUSの併用療法により,マウスのプラーク領域が著しく減少し,血管の整体性が保たれた.
結論:
- 自然に反応するNOブースター (FPG) は,内皮機能不全を効果的に標的にします.
- このアプローチは,心血管疾患に対する革新的な薬剤療法戦略の可能性を示しています.
関連する概念動画
01:28Nitric Oxide Signaling Pathway
5.2K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.2K
01:23Antihypertensive Drugs: Vasodilators
642
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
642
01:16Antianginal Drugs: Nitrates and β-Blockers
749
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
749
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
251
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
247
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
247